M&A Takeover Defenses, Antitrust Rules, and Target Valuation
Title: Corporate Finance: A Practical Approach (2nd ed.)
Authors: Michelle R. Clayman, Martin S. Fridson, George H. Troughton
ISBN: 978-1-118-10537-5
Previous: Mergers and Acquisitions: Motives and Transactions | Next: M&A Benefits, Bid Evaluation, and Restructuring
The middle chunk of Chapter 10 is where M&A stops being a strategy slide and becomes a street fight plus a math problem. Takeover defenses, antitrust regulation, and three valuation methods for targets.
Takeover defenses: the corporate moat
When a hostile bid lands, target management chooses: sell (to the bidder or someone else) or fight to stay independent. The premium offered is the biggest factor, but defenses matter.
Pre-offer defenses (set up before trouble arrives)
Courts favor these. Lawyers recommend having them in place early.
- Poison pills: shareholders get the right to buy stock at a steep discount if someone crosses an ownership threshold. Flip-in pills dilute the acquirer. Flip-over pills let target shareholders buy acquirer stock cheap. “Dead-hand” provisions make pills hard to remove without the original board.
- Poison puts: bondholders can force the company to buy back bonds at a premium after a takeover, forcing the acquirer to refinance debt immediately.
- Reincorporate in a takeover-friendly state (Ohio, Pennsylvania historically).
- Staggered boards: only a third of directors up for election each year. Takes two years minimum to win control.
- Restricted voting rights: blockholders above 15-20% cannot vote without board approval.
- Supermajority provisions: mergers need 80% approval, sometimes excluding the bidder’s shares.
- Fair price amendments: block two-tier tender offers with low second-step prices.
- Golden parachutes: big payouts to executives on change of control. Weak deterrent for large deals but may keep management at the table during negotiations.
Post-offer defenses (after the bid is public)
Courts scrutinize these harder. Targets usually combine them with pre-offer measures.
- “Just say no”: reject the bid, argue the price is too low.
- Litigation: sue over securities or antitrust violations. Rarely stops a deal but buys time.
- Greenmail: buy back the raider’s shares at a premium. Heavily taxed since 1986, largely dead.
- Share repurchase / LBO: target buys its own shares or goes private with heavy borrowing.
- Leveraged recapitalization: take on debt to repurchase shares without going fully private.
- Crown jewel defense: sell the division the bidder actually wants. Courts often block this.
- Pac-Man defense: target tries to acquire the bidder. Rare and risky.
- White knight: find a friendlier acquirer at a better price.
- White squire: sell a blocking stake to an ally without selling the whole company.
The Engelhard vs. BASF case is a textbook combo: poison pill, supermajority charter amendment, and a recapitalization tender at $45 when BASF offered $37. BASF eventually raised to $39.
Antitrust: when regulators say no
Major U.S. antitrust laws: Sherman Act (1890), Clayton Act (1914), Celler-Kefauver (1950, closed asset-purchase loophole), Hart-Scott-Rodino (1976, pre-merger notification). The FTC and DOJ review U.S. deals. The European Commission handles EU cross-border combinations.
The Herfindahl-Hirschman Index (HHI) measures market concentration. Square each firm’s market share and sum them.
- HHI below 1,000: not concentrated, challenge unlikely.
- 1,000 to 1,800: moderately concentrated. A merger raising HHI by 100+ points draws scrutiny.
- Above 1,800: highly concentrated. A 50+ point increase triggers concern.
Example: 10 firms with shares of 20%, 18%, 15%, 12%, 10%, 8%, 7%, 5%, 3%, 2%. Pre-merger HHI = 1,450. If the #2 and #3 firms merge, HHI jumps 400 points to 1,850. Likely challenge. If the two smallest merge, HHI rises only 50 points. Probably fine.
Regulators also look beyond the math: how markets are defined (geography, product scope), consumer price sensitivity, and global competition. Coca-Cola’s Cadbury Schweppes deal needed approval in 40+ jurisdictions.
Securities law: the Williams Act
The Williams Act (1968) governs tender offers in the U.S. Key rules:
- Disclose any stake above 5% (Section 13d).
- Tender offers must last at least 20 business days.
- All tendered shares get the same price.
- Shareholders can withdraw shares during the offer period.
- Target management must respond with a formal recommendation.
The point is fairness and time. No more surprise lowball offers that expire before anyone can think.
Valuing a target: three methods
1. Discounted cash flow (DCF)
Project free cash flows using pro forma statements. Discount at WACC. Add a terminal value.
FCF ≈ NOPLAT + depreciation - capex - change in working capital
Terminal value options: constant growth formula (FCF x (1+g) / (WACC - g)) or a market multiple on terminal-year FCF.
In the book’s example, terminal value was over 85% of total firm value. Small changes in growth rate or WACC swing the answer wildly.
Pros: models synergies and operational changes. Cons: terminal value dominates, long-range estimates are fragile.
2. Comparable company analysis
Find similar public companies. Calculate multiples (P/E, EV/EBITDA, EV/FCF, P/BV). Apply mean or median multiples to the target. Then add a takeover premium (historical premiums paid in similar deals, often 20-30%).
Example: New Life Books valued at $33.47 per share from comps. With a 22.9% premium, takeover price = $41.14.
Pros: market-based, data is available. Cons: inherits market mispricing, premium is a separate estimate.
3. Comparable transaction analysis
Same multiples, but applied to prices actually paid in recent acquisitions. The premium is baked in.
Medical Services valued at $47.65 per share using weighted transaction multiples.
Pros: premium included, recent market prices, reduces litigation risk on fairness. Cons: past deals may have been overpriced, few comps may exist.
Bid evaluation: who gets the synergies?
The premium formula:
Premium = Price paid - Pre-merger target value
Acquirer gain = Synergies - Premium
Post-merger value = Acquirer value + Target value + Synergies - Cash paid
The Adagio/Tantalus example shows how payment method shifts the split:
- Cash offer (€12/share): €60M premium, acquirer keeps €30M of €90M synergies.
- Stock offer (0.80 shares): €67M premium (dilution raises the cost), acquirer keeps €23M.
- Mixed offer (€6 + 0.40 shares): €64M premium, acquirer keeps €26M.
Target shareholders should prefer stock when they want to share in synergy risk and reward. Acquirers prefer cash when they are confident in synergies. Stock deals pass synergy risk to target holders. Cash deals lock in the premium for targets and leave synergy risk with the buyer.
What I took away
M&A analysis has two questions: what is the target worth, and who captures the value above that price? Defenses, antitrust, and securities law shape the battlefield. DCF, comps, and transaction multiples give you the price anchor. Premium and payment method determine the split.
The Engelhard story and the Adagio math both say the same thing: structure and negotiation matter as much as valuation.